Ras Pathway

Tumors bearing an activated Ras pathway are unable to activate the anti-viral response of the host cellular protein, PKR. In a tumor cell with an activated Ras pathway, the reovirus is able to freely replicate and kill the host tumor cell.


A proprietary variant of the reovirus based upon research conducted by the Chief Operating Officer of Oncolytics, Dr. Matt Coffey, that found the reovirus was able to infect and selectively destroy cancer cells if the cancer cells had one or more mutations on the Ras pathway.